# Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care

> **NCT01010100** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 204 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Acarbose (Glucobay, BAYG5421)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01010100
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2010-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010100, "Prevent/Delay Development of Type 2 Diabetes in Subjects With Impaired Glucose Homeostasis Treated With Acarbose in Primary Care". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01010100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*